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Abstract: The birth of a child with a disorder of sex development (DSD) prompts a long-term management 
strategy that involves a myriad of professionals working with the family. There has been progress in 
diagnosis, surgical techniques and in understanding psychosocial issues related to this condition. However, 
since these kinds of disorders are rare and have many anatomical variations, individual care is necessary, 
especially regarding surgical management. Gonadectomy is indicated in a number of intersex disorders with 
a Y chromosome to reduce the associated risk of cancer. Recently, laparoscopy has gained wide acceptance 
in pediatric urology. Laparoscopy is also reported to be a useful tool for diagnosing and treating DSD 
because of its minimal invasiveness and favorable cosmetic outcome. However, reports of evaluation and 
management using laparoscopy for large numbers of DSD patients are limited and debate is still open about 
indications and timing of gonadectomy. In this study, we reviewed the literature of the last 10 years about 
the role of laparoscopic gonadectomy in patients with DSD. In the analyzed papers, all the procedures 
were accomplished successfully using laparoscopy. No conversions to open surgery neither intra-operative 
complications were reported in all series. Post-operative complications were reported only in one series and 
included 1 umbilical port infection [2% (1/50)] and 1 pelvic abscess [2% (1/50)], both treated with antibiotic 
therapy (grade I Clavien-Dindo). Of the analyzed series, 7/10 reported postoperative diagnosis of gonadal 
tumors. The histopathologic examinations revealed 15 cases of gonadoblastoma, 7 cases of dysgerminoma 
and 2 cases of seminoma. Analyzing the single series, the incidence of these tumors varied between 10% 
and 33%. The results of our review confirmed the safety and efficacy of laparoscopic gonadectomy in DSD 
patients. In our mind, laparoscopic gonadectomy should be accepted as the treatment of choice in children 
and adolescents with these rare conditions. It thereby eliminates the risk of malignancies of gonadal origin 
with the advantages of a minimally invasive procedure, with lower morbidity, quicker postoperative recovery 
and excellent cosmetic results. 
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Definition
Disorders of sex development (DSD) are rare congenital 
anomalies with atypical  chromosome, gonadal  or 
anatomical sex organ development. DSD is a generic term 
introduced in 2005 (Chicago consensus conference) that 
applies to different congenital conditions, many of which 
are characterized by the unusual appearance of external 
genitalia and/or atypically developed gonads with potential 
negative consequences on psychosexual development, 
fertility and cancer risk. The same consensus meeting tried 
classifying these complex conditions according to their 
underlying chromosomal profiles (1,2). 
DSD is currently classified into three main groups (Table 1):
(I) The 46,XX DSD patients are individuals who 
are genetically female, most commonly due to 
Congenital Adrenal Hyperplasia (CAH), and 
present with an overdeveloped genital tubercle 
(clitoris), no vaginal connection to the perineum 
and enlarged and merged genital folds. The 
internal genitalia are female and usually normal;
(II) The 46,XY DSD patients are genetically male 
and constitute a more heterogeneous group, 
representing a spectrum from normal appearing 
females to males with hypospadias and infertility. 
These patients may have underdevelopment 
of the genital tubercle (hypospadias and/or 
micropenis) with or without undescended gonads, 
with or without feminine remnants (mullerian 
structures). Within this group are patients with 
dysfunctional gonads (gonadal dysgenesis), 
impaired steroidogenesis (17 beta hydroxysteroid 
dehydrogenase deficit), dysfunctional central 
hormonal control, and dysfunctional target 
tissues (androgen insensitivity; 5 alpha reductase 
deficiency);
(III) The chromosomal abnormalities or mosaicisms are 
mostly represented by the 45,X0/46,XY individuals 
(mixed gonadal dysgenesis). This group comprises 
the ovo-testicular DSD. These two last groups of 
patients bear both female and male genetic and 
anatomic elements. They typically have asymmetric 
genitalia with one side more masculine and the 
Table 1 DSD Classification currently adopted
46,XX DSD
A: Disorders of gonadal (ovarian) development
1. Ovotesticular DSD
2. Testicular DSD (e.g., SRY+)
3. Gonadal dysgenesis
B: Androgen excess
1. Fetal (e.g., 21 hydroxylase deficiency, 11 hydroxylase 
deficiency)
2. Fetoplacental (aromatase deficiency)
3. Maternal (luteoma, exogenous, etc.)
C: Other (e.g., cloacal extrophy, vaginal atresia, other 
syndromes)
46,XY DSD
A: Disorders of gonadal (testicular) development
1. Complete gonadal dysgenesis (Swyer syndrome)
2. Partial gonadal dysgenesis
3. Gonadal regression
4. Ovotesticular DSD
B: Disorders in androgen synthesis or action
1. Androgen biosynthesis defect (e.g., 17-hydroxysteroisd 
dehydrogenase deficiency, 5a reductase deficiency)
2. Defect in androgen action (e.g., CAIS, PAIS)
3. LH receptor defects (e.g., Leydig cell hypoplasia, aplasia)
4. Disorders of AMH and AMH receptor (Persistent Mullerian 
Duct Syndrome)
C: Other (e.g., severe hypospadias, cloacal extrophy)
Sex chromosome DSD
A: 45,X (Turner Syndrome and variants)
B: 47,XXY (Klinefelter Syndrome and variants)
C: 45,X/46,XY (Mixed Gonadal Dysgenesis, ovotesticular DSD)
D: 46,XX/46,XY (chimeric, ovotesticular DSD)
DSD, disorder of sex development.
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other side more feminine. The gonads can be testis, 
ovary or both, or dysgenetic gonads with a high 
risk for gonadal tumor development later in life.
Investigation and management of DSD
Optimal clinical management of individuals with DSD 
should comprise the following aspects: (I) gender 
assignment must be avoided prior to expert evaluation 
in newborns; (II) evaluation and long-term management 
must be performed at a center with an experienced 
multidisciplinary team; (III) all individuals should receive a 
gender assignment; (IV) open communication with patients 
and families is essential and participation in decision-
making is encouraged; (V) patient and family concerns 
should be respected and addressed in strict confidence (3).
A key point to emphasize is that the DSD child has the 
potential to become a well-adjusted, functional member 
of society. It should be explained to the parents that the 
best course of action may not initially be clear, but the 
health care team will work with the family to reach the best 
possible set of decisions in the circumstances. The health 
care team should discuss with the parents what information 
to share in the early stages with family members and friends.
Diagnostic context
The context of DSD diagnosis can be described in three 
periods of life:
Prenatally, discordance between the ultrasound 
appearance of the foetus’s genitalia and the karyotype can 
suggest a possible DSD.
A common presentation is at birth with a child born with 
unusual genitalia. In some complex cases, assignment of 
the child’s gender can be delayed by the medical team until 
the diagnostic process is completed. Assigning a gender 
based upon anatomical (phenotype) and biological criteria 
without certainty of the individual’s ultimate gender identity 
is a major challenge which is at the core of some of the 
criticisms directed at the medical team. The diagnosis can 
occur later in life, as in an individual raised as female who 
undergoes surgery for an inguinal hernia in which testis are 
found in whom primary amenorrhea is diagnosed (complete 
androgen insensitivity syndrome/Morris syndrome) or a 
girl who presents signs of virilization at puberty (5 alpha 
reductase; 17 beta hydroxysteroid reductase).
Alternatively, an individual raised as male may present 
with gynecomastia or infertility. In this group of patients, 
the gender identity is usually well established (1,2).
The multidisciplinary team
Optimal care for children with DSD requires an 
experienced multidisciplinary team that is generally found 
in tertiary care centers. Ideally, the team includes pediatric 
subspecialists in endocrinology, surgery and/or urology, 
psychology/psychiatry, gynecology, genetics, neonatology 
and, if available, social work, nursing and medical ethics (4).
Ongoing communication with the family primary care 
physician is essential (5). The team has a responsibility to 
educate other health care staff in the appropriate initial 
management of affected newborns and their families.
For new DSD patients, the team should develop a 
plan for clinical management with respect to diagnosis, 
gender assignment and treatment options before making 
any recommendations. Ideally, discussions with the family 
are conducted by one professional with appropriate 
communication skills (6). Transitional care should be 
organized with the multidisciplinary team operating in an 
environment comprising specialists with experience in both 
pediatric and adult practice. Support groups can have an 
important role in the delivery of care to DSD patients and 
their families (7).
Clinical evaluation
A family and prenatal  history,  a  general  physical 
examination with attention to any associated dysmorphic 
features and an assessment of the genital anatomy in 
comparison to published norms needs to be recorded (2). 
Criteria that suggest DSD include: (I) overt genital 
ambiguity (e.g., cloacal exstrophy); (II) apparent female 
genitalia with an enlarged clitoris, posterior labial fusion, or 
an inguinal/labial mass; (III) apparent male genitalia with 
bilateral undescended testes, micropenis, isolated perineal 
hypospadias or mild hypospadias with undescended testis; 
(IV) a family history of DSD such as complete androgen 
insensitivity syndrome (CAIS/Morris syndrome); (V) a 
discordance between genital appearance and a prenatal 
karyotype. Most causes of DSD are recognized in the 
neonatal period; later presentations in older children 
and young adults include: (I) previously unrecognized 
genital ambiguity; (II) delayed or incomplete puberty; (III) 
virilization in a female; (IV) primary amenorrhea; (V) breast 
development in a male; (VI) gross and occasionally cyclic 
hematuria in a male.
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Diagnostic evaluation
A specific molecular diagnosis is identified in only about 
20% of cases of DSD. The majority of virilized 46, XX 
infants will have congenital adrenal hyperplasia (CAH). In 
contrast, only 50% of 46 XY children with DSD will receive 
a definitive diagnosis (8,9).
Diagnostic algorithms do exist. Some tests, such as 
imaging by ultrasound, are operator dependent. Hormone 
measurements need to be interpreted in relation to the 
specific assay characteristics, and to normal values for 
gestational and chronological age. In some cases serial 
measurements may be needed.
First-line testing in newborns includes: karyotyping 
with X and Y-specific probe detection (even when 
prenatal karyotype is available), imaging (abdomino-pelvic 
ultrasound), measurement of 17-hydroxyprogesterone, 
testosterone, gonadotropins, anti-Mullerian hormone, 
serum electrolytes and urine analysis. The results of 
these investigations are generally available within 
48 hours and will be sufficient for making a working 
diagnosis. Decision making algorithms are available to 
guide further investigation (10). These include hCG and 
ACTH stimulation tests to assess testicular and adrenal 
steroid biosynthesis, urinary steroid analysis by GC mass 
spectroscopy, imaging studies and biopsies of gonadal 
material. Some gene analyses are performed in clinical 
service laboratories. 
In regard to imaging exams, a combination of ultrasound 
and magnetic resonance imaging (MRI) to determine the 
exact location of the gonads allows appropriate surgical 
planning in many cases.
What does surgery entail?
The surgeon has a responsibility to outline the surgical 
sequence and subsequent consequences from infancy to 
adulthood. Only surgeons with expertise in the care of 
children and specific training in the surgery of DSD should 
perform these procedures (1). 
Feminization procedures include the opening of the 
vaginal cavity to the perineum as in CAH or, androgen 
insensit ivity syndromes,  steroidogenesis  deficits , 
enlargement or creation of a vagina either by dilatation or 
by substitution (bowel, peritoneum), the possible reduction 
of the genital tubercle for clitoral hypertrophy with nerve 
preservation, and reconstruction of the perineum. 
Masculinization procedures include hypospadias surgery 
or, in rare cases, phalloplasty. 
Ovaries are usually preserved unless associated with 
dysgenetic testicular tissue which may carry a risk of 
malignancy.
Testes are either brought down in boys or removed 
if dysgenetic with tumor risk or in complete androgen 
insensitivity syndrome (CAIS—Morris syndrome) or 
5 alpha reductase deficiency.
Testicular prostheses can be inserted at puberty at the 
patient’s request.
Mullerian remnants can also be removed in boys if 
they cause urological (infection, dysuria) or gynecological 
(menstruation) symptoms.
The role of laparoscopy for gonadectomy in DSD 
patients
Gonadectomy is indicated in children with intersex 
disorders harboring Y chromosomal material as a result of 
the malignant potential of their gonads (11). A variety of 
tumors have been found to be frequently associated, the 
most common being the gonadoblastoma, which was found 
to a significant degree in a large case series of women with a 
Y chromosome (12).
Traditional surgery for those with intersex disorders is 
a laparotomy and bilateral gonadectomy. However, with 
increasing experience, laparoscopic evaluation of the pelvic 
structures and removal of intra-abdominal gonads has 
become a part of the management of intersex disorders. 
It is more acceptable to the patient than laparotomy. The 
widespread use of laparoscopic gonadectomy in adults 
has prompted its use in the treatment of children and 
adolescents.
Laparoscopy is well suited in this age group conferring 
advantages regarding post-operative recovery, length of 
hospitalisation and improved cosmesis. These advantages 
may reduce psychological trauma—a significant factor in 
intersex children (13).
Timing of surgery
Appropriate timing of gonadectomy hinges on an 
understanding about the different intersex disorders. The 
chances of neoplasia and virilisation in the dysgenetic or 
streak gonads found in some conditions at puberty are 
estimated at 30% (11). It has been shown that tumors can 
arise as early as six months (11).
In complete androgen insensitivity syndrome (CAIS-
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Morris syndrome), the gonads are essentially normal gonads 
with an approximately 5% risk of tumor disease. With 
complete androgen insensitivity syndrome, there is also no 
risk of virilisation at puberty as a result of lack of androgen 
response and so a prophylactic gonadectomy relatively late, 
at age 16 to 18, to allow the completion of secondary sexual 
development may be advocated.
The testes in patients with CAIS and those with partial 
androgen insensitivity syndrome (PAIS), raised female, 
should be removed to prevent malignancy in adulthood (14). 
The availability of estrogen replacement therapy allows 
for the option of early removal at the time of diagnosis 
which also takes care of the associated hernia, psychological 
problems with the presence of testes and the malignancy 
risk. Parental choice allows deferment until adolescence, 
recognizing that the earliest reported malignancy in CAIS 
is at 14 years of age (15).
The streak gonad in a patient with mixed gonadal 
dysgenesis (MGD) raised male should be removed 
laparoscopically in early childhood (14).
Bilateral gonadectomy is performed in early childhood 
in females (bilateral streak gonads) with gonadal dysgenesis 
and Y chromosome material. 
In patients with androgen biosynthetic defects raised 
female, gonadectomy should be performed before puberty.
A scrotal testis in patients with gonadal dysgenesis is at 
risk for malignancy. Current recommendations are testicular 
biopsy at puberty seeking signs of the pre-malignant lesion 
termed carcinoma-in-situ or undifferentiated intratubular 
germ cell neoplasia. If positive, the option is sperm banking 
before treatment with local low dose radiotherapy which is 
curative (16).
Risk of gonadal tumors
Interpretation of the literature is hampered by unclear 
terminology and effects of normal cell maturation delay 
(17-19). The highest tumor risk is found in TSBY (testis-
specific protein Y encoded) positive gonadal dysgenesis 
and PAIS with intra-abdominal gonads, while the lowest 
risk (<5%) is found in ovotestis (20) and CAIS (18,21). 
In the current literature, 3 categories of risk have been 
identified (1):
(I) High risk: complete gonadal dysgenesis; Partial 
gonadal dysgenesis with non-scrotal gonad; Frazier 
syndrome; Partial androgen insensitivity syndrome 
(PAIS) with non-scrotal gonad; Denys—Drash 
syndrome;
(II) Intermediate risk: 17 β-hydroxysteroid dehydrogenase 
deficiency; partial androgen insensitivity syndrome 
(PAIS) with scrotal gonad; Y-chromosome Turner 
syndrome;
(III) Low risk:  complete androgen insensit ivity 
syndrome (CAIS/Morris syndrome); ovotesticular 
DSD; Turner syndrome lacking a Y-chromosome 
in their karyotype; Persistent Müllerian duct 
syndrome.
Surgical technique
The patients have a general anaesthetic with endotracheal 
and nasogastric intubation. The video monitor, insufflator 
and light source are positioned at the foot of the patient. 
A carbon dioxide pneumoperitoneum is created using 
the open laparoscopy technique under vision through 
an umbilical incision. A 3- or 4-port laparoscopy is 
performed.
The primary10-mm port is inserted through the umbilicus 
for the 10-mm 0° telescope, and 2 or 3 secondary 3- or 
5-mm pelvic ports are inserted for working instruments. 
Laparoscopic inspection of the pelvis is carried out to 
determine the presence of gonads and to inspect the pelvic 
organs. In some cases when the gonads are not easily 
identified, the gonadal vessels are identified and followed 
down. The gonads are removed after determination of the 
course of the ureters and the fallopian tube; they are also 
excised when the gonads appear continuous with them. 
Some special hemostatic devices are used in some cases, to 
complete the resection or the hemostasis. At the end of the 
procedure, a 5-mm laparoscope is inserted through 1 of the 
lateral ports so that the gonads can be extracted through the 
central umbilical 10-mm port.
Sex steroid replacement
Hypogonadism is common in patients with dysgenetic 
gonads, defects in sex steroid biosynthesis and resistance to 
androgens.
The timing of initiation of puberty may vary but this 
is an occasion that provides an opportunity to discuss the 
condition and set a foundation for long-term adherence to 
therapy. Hormonal induction of puberty should attempt to 
replicate normal pubertal maturation to induce secondary 
sexual characteristics, a pubertal growth spurt, and optimal 
bone mineral accumulation, together with psychosocial 
support for psychosexual maturation (22). Intramuscular 
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depot injections of testosterone esters are commonly 
used in males; other options include oral testosterone 
undecanoate and transdermal preparations are also available 
(23-25). Patients with PAIS may require supraphysiologic 
doses of testosterone for optimal effect (26). Females with 
hypogonadism require estrogen supplementation to induce 
pubertal changes and menses. A progestin is usually added 
after breakthrough bleeding develops or within 1–2 years of 
continuous estrogen. There is no evidence that the addition 
of cyclic progesterone is beneficial in women without a 
uterus.
Literature analysis
Trying to find the evidence, in this review we performed a 
literature analysis using PubMed, Cochrane, and Medline 
databases on all studies published during the last 10 years 
that described laparoscopic gonadectomy in DSD patients. 
The following key words were used: “laparoscopic”, 
“gonadectomy”, “DSD”, “children”, “adolescents”, “intersex 
disorders”, “intersex patients”.
Searches were also performed using the following 
limits: clinical trials, randomized controlled trials, 
multicenter retrospective, prospective studies, and expert 
opinion. Conference abstracts were excluded because 
of the limited data presented in them. Publications with 
evidence of possible overlap were also excluded from this 
review. Although no language restrictions were imposed 
initially, the search was limited to studies published in the 
English language for the full-text review and final analysis. 
Eligibility criteria included all available studies focused 
on laparoscopic gonadectomy in DSD patients and with 
quantitative data on outcome parameters. The pediatric 
population was defined as younger than 18 years when the 
patient underwent laparoscopic gonadectomy. After relevant 
titles were identified, the abstracts of these studies were 
read to decide if the study was eligible. The full article was 
retrieved when the information in the title and/or abstract 
appeared to meet the objective of our review. The authors 
independently assessed selected studies and tabulated data 
from each article with a predefined data extraction form. 
Data regarding the following factors were considered: first 
author, publication date, study method, participant features, 
intervention characteristics, definition of complications, and 
outcome measures.
We recorded 23 studies, but only 10 papers (27-36) were 
included in the analysis since they responded to the selected 
inclusion criteria.
Results
Surgical outcome
Our review included 168 patients with various forms of 
DSD. All patients underwent laparoscopic gonadectomy; 
average age at surgery was 11.6 years (range, 3–18.3 years). 
All procedures were completed laparoscopically. Average 
operative time was 70 minutes. No conversions to open 
surgery neither intra-operative complications were reported 
in all series. Mean length of hospital stay was 1.4 days (range, 
1–2 days). 
Post-operative complications were reported only in one 
series (28) and included 1 umbilical port infection [2% 
(1/50)] and 1 pelvic abscess [2% (1/50)], both treated with 
antibiotic therapy (grade I Clavien-Dindo).
Incidence of gonadal tumors
Of the analyzed series, 7/10 reported postoperative diagnosis 
of gonadal tumors (27-30,34-36). The histopathologic 
examinations revealed 15 cases of gonadoblastoma, 7 cases 
of dysgerminoma and 2 cases of seminoma. 
Analyzing the single series, the incidence of these tumors 
varied between 10% and 33%. The majority of malignant 
tumors were reported in Total Gonadal Dysgenesis (TGD) 
and Mixed Gonadal Dysgenesis (MGD) (11 cases of 
gonadoblastoma, 6 cases of dysgerminoma), followed by 
PAIS (2 cases of seminoma, 1 case of gonadoblastoma), Y 
Turner syndrome (2 cases of gonadoblastoma), Ovotestis 
DSD (1 case of gonadoblastoma, 1 case of dysgerminoma), 
CAIS (1 case of gonadoblastoma).
Pathology revealed also benign anomalies comprising 1 
benign amartoma and 1 Sertoli cell hyperplasia in 2 patients 
with PAIS (30,34). All results are summarized in Table 2.
Discussion
In DSD patients, the first indication for gonadectomy 
is to remove the gonad, which contradicts the assigned 
social gender of the patient (29). The second indication 
for gonadectomy is to remove the dysgenetic gonad in 
patients with the presence of a Y chromosome (29). In fact, 
patients with specific forms of disorders of sex development 
harboring Y-chromosomal material have an increased risk 
for the development of cancers originating from the germ-
cell lineage, also known as germ-cell tumors (37). The risk 
of gonadal neoplasia is not confined to patients with a 46,XY 
karyotype but extends to patients with any mosaic karyotype 
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containing a Y-chromosome or the SRY antigen (11). We 
found in the literature that gonadoblastoma and seminomas 
are the most frequently occurring malignant tumors in 
gonadal intersex disorders (34).
Benign tumors such as hamartomas, Sertoli cell 
adenomas, and, rarely, Leydig-cell tumors have been 
reported in association with Morris syndrome/CAIS. 
Current recommendations for CAIS patients are to 
retain the cryptorchid gonads through puberty to receive 
benefit from their hormone production; enhance bone 
maturation; and to allow the completion of secondary sexual 
development. However, there is a high tendency to perform 
an early gonadectomy whenever a diagnosis of PAIS is 
made, in whom broad spectrum of defect mutations and 
genetic mechanisms underlying this syndrome may hide 
significant risk for malignancy (30).
To our knowledge, tests or markers that permit one 
to easily distinguish (pre)malignant from normal germ 
cells are not available. By reviewing images (computed 
tomography/magnetic resonance imaging) of these 
tumors, it is difficult to exclude possible neoplastic nature 
and preclude surgery for definitive diagnosis (30). Dénes 
et al. reported a prevalence rate of tumoral disease of 
14% but noted that only 3 of the malignant gonads had 
macroscopic abnormalities suggesting tumor (28). “In-situ” 
malignant lesions can be excluded only with histopathologic 
examination of the gonads. For these reasons, gonadectomy 
is considered the modality of choice for the treatment of 
these patients.
However, the indication for a laparoscopic abdominal 
gonadal tumor is a matter of debate in gynecologic surgery 
because of the risks of port site metastasis (38). Recent reviews 
proposed that most port site metastases occurred in cases 
with advanced disease or intra-abdominal spillage (39). Since 
gonadectomy for DSD patients is indicated as prophylactic 
surgery due to the malignant potential, this kind of surgery 
would be indicated, unless a gonadal tumor is detected by 
preoperative assessment (29).
The widespread use of laparoscopic gonadectomy in 
adults has prompted its use in the treatment of children 
and adolescents. The classic advantages of laparoscopy 
include low morbidity, excellent cosmetic results, shorter 
hospitalization, and rapid return to normal activities. In 
addition, laparoscopy gives an excellent view of the pelvic 
structures, including the genital organs (27). Laparoscopic 
evaluation can also serve as a useful surgical adjunct 
enabling better visualisation and localisation of the gonads 
and mullerian ductal remnants as well as the uterus and 
vaginal components of the urogenital sinus (29).
Another consideration is what should be done with 
normal mullerian structures. 
Consensus Statement on Management of Intersex 
Disorders in 2006 (2) and the ESPU/SPU standpoint 
on the surgical  management of  Disorders  of  Sex 
Development (1) stated that ‘In patients with a symptomatic 
utriculus, removal is best performed laparoscopically’ and 
that ‘Mullerian remnants can also be removed in boys if 
they cause urological (infection, dysuria) or gynecological 
(menstruation) symptoms’, respectively. Recently, the 
routine resection of Mullerian duct derivatives for patients 
without any symptom is not performed because literature 
rarely describes malignancy in Mullerian duct derivatives, 
with most reports involving persistent Mullerian remnant 
syndrome (38).
Preservation of the uterus is important in patients with 
Turner syndrome because there have been reports of 
pregnancy by ovum donation in this group of women (40). 
However, with regard to the fallopian tubes, it has been 
suggested that complete removal of the gonads can be best 
accomplished by adnexectomy rather than gonadectomy. 
This may be especially when the gonads are elongated, 
attenuated and closely approximated to the fallopian tube. 
It has also been suggested that as intrauterine embryo 
transfer is the preferred technique during IVF, there is less 
importance in preserving the fallopian tubes (27). 
Surgical management in DSD should also consider 
options that will facilitate the chances of fertility. In patients 
with a symptomatic utriculus, removal is best performed 
laparoscopically to increase the chance of preserving 
continuity of the vasa deferentia (2). Patients with bilateral 
ovotestes are potentially fertile from functional ovarian 
tissue (41). Separation of ovarian and testicular tissue can be 
technically difficult and should be undertaken, if possible, in 
early life.
It has been reported that oocyte cryopreservation is a 
feasible technique in selected post-pubertal female children 
at risk for premature ovarian failure and infertility as 
happens in Turner syndrome (42,43). In our review, only 
1 series reported ovarian cryopreservation in an attempt to 
maintain the fertility of patients with Turner syndrome (34).
In all series reported in this review, all laparoscopic 
surgeries  were completed without  convers ion to 
open surgery, significant bleeding, or intraoperative 
complications. In addition, besides laparoscopy having the 
advantages of being a minimally invasive approach, a more 
favorable cosmetic result is also an important factor for 
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young patients already involved in complex psychological 
and social relationships. This is another advantage of 
laparoscopy for patients with DSD (27,29).
However, debate is still open about indications and 
timing of gonadectomy. Based on the non trascurabile rate 
of tumoral risk reported in our review, variable between 
10% and 33%, the availability of estrogen replacement 
therapy to allow secondary sexual development and the 
performance of cryopreservation to preserve fertility 
allow for the option of early gonadectomy at the time of 
diagnosis.
We believe that laparoscopic gonadectomy should 
be accepted as the treatment of choice in children and 
adolescents with these rare conditions. It thereby eliminates 
the risk of malignancies of gonadal origin with the 
advantages of a minimally invasive procedure, with lower 
morbidity, quicker postoperative recovery and excellent 
cosmetic results. This latter aspect is especially important 
for patients with intersex disorders who need reaffirmation 
of their body image and self-esteem.
In addition, it should be offered within a specialist unit 
offering the full range of multidisciplinary medical and 
psychological support for children and teenagers with these 
complex conditions.
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